Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the application priority review. The agency set a Prescription Drug User Fee Act action date of Feb. 12, 2027.
Chairman and Chief Executive Officer Dr. Tom Lin said the company is approaching a potential U.S. regulatory approval and is continuing pre-commercial preparations while engaging with medical and patient communities. He said the company views the acceptance of its application as reflecting the “strength, consistency, and depth” of clinical data generated across its development program.
DRAGON data presented at retina meetings
According to Lin, patients treated with tinlarebant showed halted to slightly reduced QAF values, declining by about 2% at month 25 versus baseline. Patients in the placebo group, meanwhile, had an approximately 20% increase in QAF values over the same period.
Lin said QAF is a marker of toxic lipofuscin retinal accumulation, which he described as a key driver of retinal degeneration in Stargardt disease. He said prevention or reduction of QAF is aligned with tinlarebant’s mechanism of action and could support the drug’s potential to halt or slow lesion growth.
Expenses and quarterly loss increased
Chief Financial Officer Hao-Yuan Chuang said second-quarter research and development expenses rose to $18.2 million from $11 million in the year-earlier period. The increase was primarily attributed to a royalty payment tied to an additional milestone under a licensing agreement.
On a non-GAAP basis, excluding share-based compensation, R&D expenses were $17.2 million, compared with $8.6 million in the second quarter of 2025.
Selling, general and administrative expenses increased to $16.7 million from $6.5 million a year earlier, primarily due to higher professional service fees, wages and salaries associated with team expansion. Non-GAAP SG&A expenses were $10.9 million, compared with $1.3 million in the prior-year quarter.
Belite Bio reported a GAAP net loss of $28.4 million for the second quarter, compared with a $16.3 million loss a year earlier. Its non-GAAP net loss was $21.6 million, compared with $8.7 million in the comparable 2025 period.
The company ended the quarter with $780 million in cash equivalents and U.S. Treasury bills. Chuang said Belite Bio believes its balance sheet provides sufficient funding to commercialize tinlarebant following a potential regulatory approval and to continue advancing its pipeline.
Regulatory and development plans
In response to analyst questions, Lin said the company currently views its DRAGON II trial as a Japan-focused study for the Pharmaceuticals and Medical Devices Agency, or PMDA, and does not expect it to contribute to the U.S. NDA process at this stage.
Chief Medical Officer Dr. Hendrik Scholl said Belite Bio is initiating a pediatric investigation plan study in London to evaluate tinlarebant in patients ages 3 through 11. The study is intended to inform regulatory processes for patients younger than 12.
Lin said the company is concentrating on the FDA review ahead of the February 2027 PDUFA date and expects a European filing to occur after a potential FDA approval. He said the approach would allow the company to align regulatory communications outside the U.S. with discussions and outcomes from the FDA review.
The company has U.S. and ex-U.S. contract development and manufacturing organizations, Lin said, though it did not identify them. He also said Belite Bio does not currently believe an FDA advisory committee meeting is being planned, while noting the agency could decide to use one later in the review process.
Voucher, Japan filing and geographic atrophy update
Chuang said Belite Bio expects to receive a priority review voucher if tinlarebant is approved, based on the drug’s rare pediatric disease designation. The company has not decided whether it would sell or use the voucher, he said, adding that management will continue to assess market conditions and its pipeline.
Lin said the company expects its interim analysis for its geographic atrophy study to move into the first quarter of 2027, likely after February, as the FDA review of tinlarebant will be its top priority during December and January.
Regarding Japan, Lin said PMDA activities are proceeding in parallel with the FDA submission. He said that, given tinlarebant’s Sakigake designation, the company expects Japan could potentially approve the drug about three months after an FDA approval.
Scholl said Belite Bio does not want to comment on a potential U.S. label while the NDA remains under review. However, he said lesion-growth progression is not dramatically different across age groups based on the PHOENIX study and that the underlying cause of disease is the same across patient ages. Separately, Chief Scientific Officer Dr. Nathan Mata said dosing compliance in DRAGON II was in excess of 90% after 24 months.
About Belite Bio (NASDAQ:BLTE)
Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.
Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.
